Idorsia Ltd (IDIA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Idorsia Ltd (IDIA) has a cash flow conversion efficiency ratio of 0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-26.63 Million ≈ $-33.67 Million USD) by net assets (CHF-1.18 Billion ≈ $-1.49 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Idorsia Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Idorsia Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Idorsia Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Idorsia Ltd for real-time trading data and today's change.
Idorsia Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Idorsia Ltd ranked by their cash flow conversion efficiency. Review cash generation quality of Idorsia Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EmbedWay Tech(Shanghai)Corp
SHG:603496
|
0.038x |
|
J.Pond Precision Technology Co. Ltd. A
SHE:301326
|
N/A |
|
Corporación Interamericana de Entretenimiento S.A.B. de C.V
MX:CIEB
|
-0.085x |
|
Trupanion Inc
NASDAQ:TRUP
|
0.051x |
|
Xining Special Steel Co Ltd
SHG:600117
|
-0.005x |
|
Coretronic
TWO:5371
|
-0.004x |
|
Central Plains Environment Protection Co Ltd
SHE:000544
|
0.014x |
|
Beijing Jingyuntong Technology Co Ltd
SHG:601908
|
0.063x |
Annual Cash Flow Conversion Efficiency for Idorsia Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Idorsia Ltd from 2016 to 2025. Also see IDIA current and non-current assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF-1.14 Billion ≈ $-1.44 Billion |
CHF-153.23 Million ≈ $-193.72 Million |
0.135x | -55.88% |
| 2024-12-31 | CHF-1.21 Billion ≈ $-1.53 Billion |
CHF-370.23 Million ≈ $-468.07 Million |
0.305x | -52.98% |
| 2023-12-31 | CHF-968.72 Million ≈ $-1.22 Billion |
CHF-629.30 Million ≈ $-795.60 Million |
0.650x | -50.02% |
| 2022-12-31 | CHF-660.96 Million ≈ $-835.63 Million |
CHF-859.11 Million ≈ $-1.09 Billion |
1.300x | +122.96% |
| 2021-12-31 | CHF104.20 Million ≈ $131.74 Million |
CHF-589.89 Million ≈ $-745.79 Million |
-5.661x | -808.88% |
| 2020-12-31 | CHF585.48 Million ≈ $740.21 Million |
CHF-364.67 Million ≈ $-461.04 Million |
-0.623x | +77.85% |
| 2019-12-31 | CHF164.35 Million ≈ $207.78 Million |
CHF-462.04 Million ≈ $-584.14 Million |
-2.811x | -424.02% |
| 2018-12-31 | CHF657.62 Million ≈ $831.42 Million |
CHF-352.82 Million ≈ $-446.06 Million |
-0.537x | -515.46% |
| 2017-12-31 | CHF739.51 Million ≈ $934.94 Million |
CHF95.50 Million ≈ $120.73 Million |
0.129x | +124.91% |
| 2016-12-31 | CHF507.97 Million ≈ $642.21 Million |
CHF-263.34 Million ≈ $-332.93 Million |
-0.518x | -- |
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more